Smith Group Asset Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Smith Group Asset Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-6,680	Closed	-$120K	–	473
2017 Q4	$120K	Hold	6,680	–	–	﹤0.01%	276
2017 Q3	$79K	Sell	6,680 -570	-8%	-$6.39K	﹤0.01%	298
2017 Q2	$76K	Sell	7,250 -3,360	-32%	-$34.3K	﹤0.01%	301
2017 Q1	$117K	Hold	10,610	–	–	﹤0.01%	295
2016 Q4	$144K	Sell	10,610 -340	-3%	-$4.74K	﹤0.01%	283
2016 Q3	$135K	Buy	10,950 +220	+2%	+$2.59K	﹤0.01%	291
2016 Q2	$118K	Buy	10,730 +4,400	+70%	+$49.3K	﹤0.01%	304
2016 Q1	$69K	Buy	6,330 +3,920	+163%	+$49.5K	﹤0.01%	292
2015 Q4	$42K	Buy	2,410 +460	+24%	+$8.25K	﹤0.01%	347
2015 Q3	$39K	Buy	+1,950	New	+$44.7K	﹤0.01%	294
2014 Q3	–	Sell	-2,730	Closed	-$19K	–	444
2014 Q2	$19K	Hold	2,730	–	–	﹤0.01%	308
2014 Q1	$20K	Hold	2,730	–	–	﹤0.01%	296
2013 Q4	$26K	Buy	+2,730	New	+$19.5K	﹤0.01%	273

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Smith Group Asset Management's SCMP Position: Q1 2018 in Review

Smith Group Asset Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 6,680 shares — an estimated $120K sold.

Smith Group Asset Management first reported a position in SCMP in Q4 2013 and held it in 13 quarters. The position peaked at $144K in Q4 2016. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

Smith Group Asset Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Smith Group Asset Management sold 6,680 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $120K.
Smith Group Asset Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2013 and held it in 13 quarters.
Smith Group Asset Management's Sucampo Pharmaceuticals, Inc. position peaked at $144K in Q4 2016.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Smith Group Asset Management's 13F filing for Q1 2018, filed 8 May 2018.